Overview

Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol

Status:
Terminated
Trial end date:
2018-03-15
Target enrollment:
Participant gender:
Summary
The main purpose is to determine whether Triferic, administered orally with Shohl's solution, is safe and effective for the treatment of iron-refractory iron-deficiency anemia (IRIDA).
Phase:
Phase 2
Details
Lead Sponsor:
Rockwell Medical Technologies, Inc.
Treatments:
Citric Acid
Iron
Pharmaceutical Solutions
Sodium Citrate